Search
Biospace news
RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 49 weeks 6 days ago
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data 6/7/2024
FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm
FDA Raises Concerns About Lilly’s Donanemab Alzheimer’s Candidate Ahead of Adcomm 6/7/2024
FDA Approves Geron’s First-in-Class Telomerase Inhibitor for Blood Disorder
FDA Approves Geron’s First-in-Class Telomerase Inhibitor for Blood Disorder 6/7/2024
Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate
Biomea’s Stock Nosedives More Than 60% as FDA Puts Clinical Hold on Diabetes Candidate 6/7/2024
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24 6/7/2024
AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win
AbbVie Sees Early ROI on $10B Immunogen Buy in Phase II Ovarian Cancer Win 6/7/2024
Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA
Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA 6/7/2024
Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome
Flagship-Backed Prologue Launches with $50M to DELVE into Viral Proteome 5/7/2024
Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performance
Vertex Touts 13% Revenue Jump, Beats Profit Estimates on Strong Cystic Fibrosis Performance 5/7/2024
AAV Manufacturing Takes Center Stage at ASGCT24
AAV Manufacturing Takes Center Stage at ASGCT24 5/7/2024
ADC Therapeutics Posts Early Phase II Lymphoma Data for Zynlonta as Revenue Drops 5.8%
ADC Therapeutics Posts Early Phase II Lymphoma Data for Zynlonta as Revenue Drops 5.8% 5/7/2024
Preliminary Findings Point to Low Risk of Secondary Cancers from CAR-T Therapies
Preliminary Findings Point to Low Risk of Secondary Cancers from CAR-T Therapies 5/7/2024
FDA Sets Date for Eli Lilly’s Donanemab Adcomm While Pondering Changes to Format
FDA Sets Date for Eli Lilly’s Donanemab Adcomm While Pondering Changes to Format 5/7/2024
FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info
FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info 6/28/2024
Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate
Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate 6/28/2024
ICER Doubles Down on Critique of Lykos’ MDMA Therapy, Cites Data Concerns
ICER Doubles Down on Critique of Lykos’ MDMA Therapy, Cites Data Concerns 6/28/2024
FDA Needs to Step Up As Use of Third-Party Manufacturers Leads to Rejections
FDA Needs to Step Up As Use of Third-Party Manufacturers Leads to Rejections 6/28/2024
With Latest Expansion in Ohio, Resilience Can Best Serve Partners and Patients
With Latest Expansion in Ohio, Resilience Can Best Serve Partners and Patients 6/28/2024
Illumina Reports $1.47B ‘Goodwill’ Impairment Charge After Grail Spinoff
Illumina Reports $1.47B ‘Goodwill’ Impairment Charge After Grail Spinoff 6/28/2024
AbbVie Expands Immuno Portfolio With $250M Celsius Buy as Humira Hits Patent Cliff
AbbVie Expands Immuno Portfolio With $250M Celsius Buy as Humira Hits Patent Cliff 6/28/2024
World Pharma News
- Researchers develop potent CDK9 inhibitor to overcome drug resistance in hematological malignancies
- Research opens up new avenue for tuberculosis drug discovery
- Aggressive skin cancer driven by mitochondrial processes - existing drugs offer promising treatment path
- Study highlights major hurdles for multinational clinical trials in Europe
- New model to find treatments for an aggressive blood cancer